Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.92 and traded as high as $4.02. Brainstorm Cell Therapeutics shares last traded at $4.02, with a volume of 1,100 shares trading hands.
Separately, ValuEngine cut Brainstorm Cell Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th.
The company has a current ratio of 0.52, a quick ratio of 0.52 and a debt-to-equity ratio of 9.34. The company has a fifty day simple moving average of $3.82 and a 200-day simple moving average of $3.92. The company has a market capitalization of $89.75 million, a PE ratio of -5.53 and a beta of 1.24.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.12). On average, equities analysts predict that Brainstorm Cell Therapeutics Inc will post -0.68 EPS for the current fiscal year.
In other news, Director Irit Arbel sold 13,332 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $3.67, for a total transaction of $48,928.44. Following the completion of the transaction, the director now directly owns 162,499 shares in the company, valued at approximately $596,371.33. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 22.60% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Delek Group Ltd. purchased a new position in shares of Brainstorm Cell Therapeutics during the 1st quarter worth $183,000. CIBC Private Wealth Group LLC grew its holdings in shares of Brainstorm Cell Therapeutics by 349.9% during the 1st quarter. CIBC Private Wealth Group LLC now owns 67,484 shares of the biotechnology company’s stock worth $293,000 after purchasing an additional 52,484 shares during the period. BlackRock Inc. grew its holdings in shares of Brainstorm Cell Therapeutics by 44.6% during the 2nd quarter. BlackRock Inc. now owns 130,281 shares of the biotechnology company’s stock worth $514,000 after purchasing an additional 40,197 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in shares of Brainstorm Cell Therapeutics by 10.7% during the 2nd quarter. Renaissance Technologies LLC now owns 224,377 shares of the biotechnology company’s stock worth $886,000 after purchasing an additional 21,720 shares during the period. Institutional investors and hedge funds own 8.55% of the company’s stock.
About Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.